New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 14, 2013
05:55 EDTDVA, DVA, WLP, WLP, MCK, MCK, CI, CI, BMY, BMY, MDT, MDT, COV, COV, BAYRY, BAYRY, EPOC, EPOC, AET, AET, AGN, AGN, HUM, HUM, BDX, BDXWharton School of Business to host a conference
19th Annual Wharton Healthcare Business Conference is being held in Philadelphia on February 14-15.
News For DVA;HUM;AGN;AET;EPOC;BAYRY;COV;MDT;BMY;CI;MCK;WLP;BDX From The Last 14 Days
Check below for free stories on DVA;HUM;AGN;AET;EPOC;BAYRY;COV;MDT;BMY;CI;MCK;WLP;BDX the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | all recent news | >>
August 19, 2014
08:40 EDTMDTMedtronic sees FY15 gross margin of 74.5%-75%, with Q2 on lower end of range
Subscribe for More Information
08:25 EDTMDTMedtronic: Negative factors in Spine segment in Q1 werre temporary
Subscribe for More Information
08:22 EDTCOV, MDTMedtronic: We will continue to pay significant US taxes following Covidien deal
Subscribe for More Information
07:19 EDTMDTMedtronic backs FY15 EPS view of $4.00-$4.10, consensus $4.04
Subscribe for More Information
07:17 EDTMDTMedtronic reports Q1 EPS 93c, consensus 92c
Reports Q1 revenue $4.27B, consensus $4.25B.
August 18, 2014
16:10 EDTCOVCovidien says study shows directional atherectomy safe, effective
Covidien announced that directional atherectomy is "safe and effective as a frontline therapy for the treatment of peripheral arterial disease," according to a Covidien study published online today in the Journal of American College of Cardiology, Cardiovascular Interventions. Results from the DEFINITIVE LE study using Covidienís TurboHawk and/or SilverHawk directional atherectomy systems demonstrated 95% limb salvage in patients with critical limb ischemia and 78% overall patency in claudicant patients at 12 months.
15:59 EDTAGNAllergan CFO change may suggest strategic deal near, says BMO Capital
BMO Capital believes former Allergan (AGN) CFO Jeff Edwards would not be leaving if a change of control of the company, such as a takeover by Valeant (VRX), were in the future. Rather, BMO thinks Edwards' decision to leave could be a sign that a strategic transaction marking a new chapter in Allergan's growth may be nearing. The firm thinks Allergan is in capable hands with new CFO Jim Hindman and it keeps an Outperform rating on the stock with a $230 price target.
15:26 EDTMDTNotable companies reporting before tomorrow's open
Subscribe for More Information
14:49 EDTMDTMedtronic technical comments before earnings
Subscribe for More Information
13:59 EDTMDTMedtronic August weekly 63.5 straddle priced for 2% move into Q1
Subscribe for More Information
11:57 EDTAGNAllergan CFO departure largely unexpected, says Wells Fargo
Subscribe for More Information
09:02 EDTAGNAllergan names Jim Hindman as CFO, effective immediately
Subscribe for More Information
07:57 EDTBMY, AGNCambridge Healthtech Institute to hold a summit
6th Annual Bioprocessing Summit to be held in Boston on August 18-22.
06:24 EDTMDTOptions expected to be active
Subscribe for More Information
August 15, 2014
17:03 EDTAGNValeant extends offer to acquire Allergan
Valeant Pharmaceuticals (VRX) announced that it has extended the expiration of its exchange offer to acquire all of the outstanding shares of Allergan (AGN) to December 31. The exchange offer was previously scheduled to expire August 15. All other terms and conditions of the exchange offer remain unchanged.
14:14 EDTAGNValeant being probed by IRS after Biovail deal, FT says
Subscribe for More Information
10:01 EDTDVAOn The Fly: Analyst Downgrade Summary
Today's noteworthy downgrades include: Apollo Global (APO) downgraded to Market Perform from Outperform at Wells Fargo... Calavo Growers (CVGW) downgraded to Neutral from Outperform at Wedbush... DaVita (DVA) downgraded to Hold from Buy at Deutsche Bank... Dangdang (DANG) downgraded to Neutral from Outperform at Credit Suisse... Ducommun (DCO) downgraded to Neutral from Buy at DA Davidson... Energy XXI (EXXI) downgraded to Sector Perform from Outperform at Howard Weil... Fifth Street Finance (FSC) downgraded to Neutral from Buy at Gilford Securities... Genetic Technologies (GENE) downgraded to Neutral from Buy at Ladenburg... Harmony Gold (HMY) downgraded to Underweight from Neutral at HSBC... Ignite Restaurant (IRG) downgraded to Neutral from Overweight at Piper Jaffray... JDSU (JDSU) downgraded to Hold from Buy at Argus... K12 (LRN) downgraded to Market Perform from Outperform at Wells Fargo... KKR (KKR) downgraded to Market Perform from Outperform at Wells Fargo... Lexington Realty (LXP) downgraded to Neutral from Buy at Ladenburg... Lithia Motors (LAD) downgraded to Underweight from Equal Weight at Morgan Stanley... New York & Co. (NWY) downgraded to Neutral from Buy at Janney Capital... OCI Partners (OCIP) downgraded to Underweight from Equal Weight at Barclays... OmniVision (OVTI) downgraded to Neutral from Outperform at RW Baird... Smith & Nephew (SNN) downgraded to Equal Weight from Overweight at Morgan Stanley... Subsea 7 (SUBCY) downgraded to Neutral from Buy at Goldman... Tencent (TCEHY) downgraded to Neutral from Overweight at JPMorgan... ViaSat (VSAT) downgraded to Equal Weight from Overweight at Stephens... bebe stores (BEBE) downgraded to Neutral from Buy at Janney Capital.
09:45 EDTAGNEvent-driven funds, Pershing own over 20% of Allergan, CNBC reports
Event-driven hedge funds and Pershing Square owned over 20% of Allergan as of June 30, CNBC's David Faber reports. Valeant (VRX) and Pershing are seen as getting the over 30% to call a special meeting, Faber adds.
07:30 EDTDVADaVita downgraded to Hold from Buy at Deutsche Bank
Subscribe for More Information
05:44 EDTDVADaVita downgraded to Hold from Buy at Deutsche Bank
1 | 2 | 3 | 4 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use